Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q4 Loss of $0.33
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $291.37 -0.61%
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
CGEH, NAKA, APOG, More
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q4 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $20.9 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
